BNR.US

Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to growth after more than a year of declines. Its net loss narrowed to 35.7 million yuan from a 175 million yuan loss a year earlier.

The company said revenue from its in-hospital business, where it processes results for its cancer tests in labs based within hospitals, rose 17% to 63.8 million yuan year-on-year. But revenue from its central laboratory business, which requires testing samples to be sent to off-site labs, fell 25.2% to 40 million yuan.

Burning Rock and its peers have suffered over the last year from an anti-corruption drive in the medical industry. That campaign has taken a big toll on the company’s central laboratory business, which is especially prone to corruption due to its reliance on physician referrals.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Chinese government pumping confidence into stock market

China’s state-driven stocks, and its corporate wars abroad

China's stock market rally is fast approaching its one-year mark, with the benchmark Hang Seng and Shanghai composite indexes both up around 40%. How much longer can it last, especially given the weak state of China's economy? And internet giants Meituan and DiDi have sued each other in Brazil, where they are competing in the takeout dining market. How is this case likely to end up?